London's FTSE 100 pushes higher in early dealings, extending a 'Super Thursday' surge following the Bank of England's stimulus boost. One of the day's biggest corporate stories involves Royal Bank of Scotland (RBS), which reports a widening of interim losses from £179 million to £2 billion due to rising insurance mis-selling compensation demands and other litigation costs. The UK-focused lender ...

UK investors react positively to the gains seen overnight on Wall Street after the release of the last set of Fed minutes which appear to point to a shallower path for interest rate increases over the coming year. That sends the FTSE 100 soaring, the index up nearly 70 points, or 1.1%, to 6,348, with mid and small caps also firmly higher. In corporate news, Johnson Matthey (JMAT) jumps 7% to ...

Investors change tack in mid-morning trade on Friday propping up London share prices after initial declines across the market. The clue-chip FTSE 100 index adds around 25 points, or 0.35%, to 6,679 with similar gains being chalked-up across the wider FTSE All-Share index. But midcaps struggle to overcome several negative corporate announcements from FTSE 250 companies, including miner Lonmin ...

UK stocks open largely flat on Monday with markets pausing for breath after hitting a two-month high last week. The FTSE 100 is trading roughly 4 points higher at 6,754 in early deals, with oilfield services group Petrofac (PFC) providing a drag after a profit warning. The index finished Friday at 6,750.76, a closing level not surpassed since 22 September when it reached 6,773.63. Oil ...

Greene King upgrade hope After a bullish trading update with strong Christmas takings, analysts reckon Greene King (GNK) could be in line for earnings upgrades if it can maintain the positive sales momentum into the new year. The pubs operator has soft comparative numbers to beat in January and March. (DC)   Cloudy future Investors will get a steer on how accounting ...

It was a long time coming and when it finally came it arrived from Burton-on-Trent. On 25 September a new pharmaceutical stock was presented to investors when Clinigen (CLIN:AIM) became the first in the sector to list in London since 2007. It was worth the wait. Revenues had grown 242% in two years, while sales forces on three continents and an ambitious chief executive were looking to ...